Postpartum haemorrhage (PPH) remains the leading cause of pregnancy-related deaths worldwide. Typically, bleeding is controlled by timely obstetric measures in parallel with resuscitation and treatment of coagulopathy. Early recognition of abnormal coagulation is crucial and haemostatic support should be considered simultaneously with other strategies as coagulopathies contribute to the progression to massive haemorrhage. However, there is lack of agreement on important topics in the current guidelines for management of PPH. A clinical definition of PPH is paramount to understand the situation to which the treatment recommendations relate; however, reaching a consensus has previously proven difficult. Traditional definitions are based on volume of blood loss, which is difficult to monitor, can be misleading and leads to treatment delay. A multidisciplinary approach to define PPH considering vital signs, clinical symptoms, coagulation and haemodynamic changes is needed. Moreover, standardised algorithms or massive haemorrhage protocols should be developed to reduce the risk of morbidity and mortality and improve overall clinical outcomes in PPH. If available, point-of-care testing should be used to guide goal-directed haemostatic treatment. Tranexamic acid should be administered as soon as abnormal bleeding is recognised. Fibrinogen concentrate rather than fresh frozen plasma should be administered to restore haemostasis where there is elevated risk of fibrinogen deficiency (e.g., in catastrophic bleeding or in cases of abruption or amniotic fluid embolism) as it is a more concentrated source of fibrinogen. Lastly, organisational considerations are equally as important as clinical interventions in the management of PPH and have the potential to improve patient outcomes.

From the Department of Anaesthesiology Westpfalz Klinikum Kaiserslautern Germany

000      

00000naa a2200000 a 4500

001      

bmc22032076

003      

CZ-PrNML

005      

20230131150719.0

007      

ta

008      

230120s2023 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1097/EJA.0000000000001744 $2 doi

035    __

$a (PubMed)36131564

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Hofer, Stefan $u From the Department of Anaesthesiology, Westpfalz-Klinikum Kaiserslautern, Germany (SH), the Department of Anaesthesiology and Intensive Care Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic (JB), the School of Medicine, Cardiff University, Cardiff, UK (PWC), the Department of Anaesthesiology and Critical Care Medicine, Obstetrics Unit, CHU de Lille, Lille, France (ASDB), the Anaesthesia and Intensive Care Department, Hospital Universitario La Paz, Madrid, Spain (EG), the Department of Obstetrics and Gynaecology, V Cervello Hospital, Palermo, Italy (FrL), the Department of Anaesthesiology, Hospital de Santa Maria, Lisbon, Portugal (FiL), the Department of Gynaecology and Obstetrics, Drammen Hospital, Norway (LTN), the Institute for Anaesthesia and Intensive Care Medicine, LKH Rohrbach, Rohrbach, Austria (KS), the Department of Anaesthesiology, UZ Leuven, Leuven, Belgium (MVdV)

245    10

$a Haemostatic support in postpartum haemorrhage: A review of the literature and expert opinion / $c S. Hofer, J. Blaha, PW. Collins, AS. Ducloy-Bouthors, E. Guasch, F. Labate, F. Lança, LT. Nyfløt, K. Steiner, M. Van de Velde

520    9_

$a Postpartum haemorrhage (PPH) remains the leading cause of pregnancy-related deaths worldwide. Typically, bleeding is controlled by timely obstetric measures in parallel with resuscitation and treatment of coagulopathy. Early recognition of abnormal coagulation is crucial and haemostatic support should be considered simultaneously with other strategies as coagulopathies contribute to the progression to massive haemorrhage. However, there is lack of agreement on important topics in the current guidelines for management of PPH. A clinical definition of PPH is paramount to understand the situation to which the treatment recommendations relate; however, reaching a consensus has previously proven difficult. Traditional definitions are based on volume of blood loss, which is difficult to monitor, can be misleading and leads to treatment delay. A multidisciplinary approach to define PPH considering vital signs, clinical symptoms, coagulation and haemodynamic changes is needed. Moreover, standardised algorithms or massive haemorrhage protocols should be developed to reduce the risk of morbidity and mortality and improve overall clinical outcomes in PPH. If available, point-of-care testing should be used to guide goal-directed haemostatic treatment. Tranexamic acid should be administered as soon as abnormal bleeding is recognised. Fibrinogen concentrate rather than fresh frozen plasma should be administered to restore haemostasis where there is elevated risk of fibrinogen deficiency (e.g., in catastrophic bleeding or in cases of abruption or amniotic fluid embolism) as it is a more concentrated source of fibrinogen. Lastly, organisational considerations are equally as important as clinical interventions in the management of PPH and have the potential to improve patient outcomes.

650    _2

$a lidé $7 D006801

650    _2

$a ženské pohlaví $7 D005260

650    12

$a hemostatika $x terapeutické užití $7 D006490

650    12

$a poporodní krvácení $x diagnóza $x terapie $7 D006473

650    _2

$a fibrinogen $7 D005340

655    _2

$a přehledy $7 D016454

655    _2

$a časopisecké články $7 D016428

700    1_

$a Blaha, Jan

700    1_

$a Collins, Peter W

700    1_

$a Ducloy-Bouthors, Anne-Sophie

700    1_

$a Guasch, Emilia

700    1_

$a Labate, Francesco

700    1_

$a Lança, Filipa

700    1_

$a Nyfløt, Lill Trine

700    1_

$a Steiner, Kostja

700    1_

$a Van de Velde, Marc

773    0_

$w MED00001596 $t European journal of anaesthesiology $x 1365-2346 $g Roč. 40, č. 1 (2023), s. 29-38

856    41

$u https://pubmed.ncbi.nlm.nih.gov/36131564 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20230120 $b ABA008

991    __

$a 20230131150715 $b ABA008

999    __

$a ok $b bmc $g 1891072 $s 1183411

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 40 $c 1 $d 29-38 $e 20220922 $i 1365-2346 $m European journal of anaesthesiology $n Eur J Anaesthesiol $x MED00001596

LZP    __

$a Pubmed-20230120